APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Attention-Deficit Hyperactivity Disorder (ADHD) Medications

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Growth and Trends Forecast to 2032

Report ID 173968210127 December 2025102 pages

Choose your research edition.

Industry ResearchAttention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Attention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

According to APO Research, the global Attention-Deficit Hyperactivity Disorder (ADHD) Medications market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Attention-Deficit Hyperactivity Disorder (ADHD) Medications is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Attention-Deficit Hyperactivity Disorder (ADHD) Medications is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Attention-Deficit Hyperactivity Disorder (ADHD) Medications is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Attention-Deficit Hyperactivity Disorder (ADHD) Medications market include The Takeda Pharmaceutical Company Limited, Novartis AG, Eli Lilly and Company, Pfizer Inc., Supernus Pharmaceutical,Inc., purdue Pharma L.P., Neos Therapeutics Inc., Mallinckrodt Pharmaceuticals and Lupin Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Attention-Deficit Hyperactivity Disorder (ADHD) Medications market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Attention-Deficit Hyperactivity Disorder (ADHD) Medications market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Attention-Deficit Hyperactivity Disorder (ADHD) Medications market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Attention-Deficit Hyperactivity Disorder (ADHD) Medications.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Attention-Deficit Hyperactivity Disorder (ADHD) Medications market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market by Company

The Takeda Pharmaceutical Company Limited

Novartis AG

Eli Lilly and Company

Pfizer Inc.

Supernus Pharmaceutical,Inc.

purdue Pharma L.P.

Neos Therapeutics Inc.

Mallinckrodt Pharmaceuticals

Lupin Limited

Johnson & Johnson

Attention-Deficit Hyperactivity Disorder (ADHD) Medications Segment by Type

Stimulants

Non-stimulants

Attention-Deficit Hyperactivity Disorder (ADHD) Medications Segment by Application

Hospital

Clinic

Others

Attention-Deficit Hyperactivity Disorder (ADHD) Medications Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attention-Deficit Hyperactivity Disorder (ADHD) Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Attention-Deficit Hyperactivity Disorder (ADHD) Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attention-Deficit Hyperactivity Disorder (ADHD) Medications.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Attention-Deficit Hyperactivity Disorder (ADHD) Medications companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Region (2021-2026) Table 4. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Region (2027-2032) Table 6. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Share by Type (2021-2026) Table 9. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Share Forecasted by Type (2027-2032) Table 11. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Share by Application (2021-2026) Table 24. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Share Forecasted by Application (2027-2032) Table 26. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Trends Table 37. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Drivers Table 38. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Opportunities and Challenges Table 39. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Restraints Table 40. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue Market Share by Company (2021-2026) Table 42. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Key Company Headquarters & Area Served Table 44. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Company, Product Type & Application Table 45. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. The Takeda Pharmaceutical Company Limited Company Information Table 49. The Takeda Pharmaceutical Company Limited Business Overview Table 50. The Takeda Pharmaceutical Company Limited Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. The Takeda Pharmaceutical Company Limited Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio Table 52. The Takeda Pharmaceutical Company Limited Recent Development Table 53. Novartis AG Company Information Table 54. Novartis AG Business Overview Table 55. Novartis AG Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Novartis AG Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio Table 57. Novartis AG Recent Development Table 58. Eli Lilly and Company Company Information Table 59. Eli Lilly and Company Business Overview Table 60. Eli Lilly and Company Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Eli Lilly and Company Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio Table 62. Eli Lilly and Company Recent Development Table 63. Pfizer Inc. Company Information Table 64. Pfizer Inc. Business Overview Table 65. Pfizer Inc. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Pfizer Inc. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio Table 67. Pfizer Inc. Recent Development Table 68. Supernus Pharmaceutical,Inc. Company Information Table 69. Supernus Pharmaceutical,Inc. Business Overview Table 70. Supernus Pharmaceutical,Inc. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Supernus Pharmaceutical,Inc. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio Table 72. Supernus Pharmaceutical,Inc. Recent Development Table 73. purdue Pharma L.P. Company Information Table 74. purdue Pharma L.P. Business Overview Table 75. purdue Pharma L.P. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. purdue Pharma L.P. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio Table 77. purdue Pharma L.P. Recent Development Table 78. Neos Therapeutics Inc. Company Information Table 79. Neos Therapeutics Inc. Business Overview Table 80. Neos Therapeutics Inc. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Neos Therapeutics Inc. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio Table 82. Neos Therapeutics Inc. Recent Development Table 83. Mallinckrodt Pharmaceuticals Company Information Table 84. Mallinckrodt Pharmaceuticals Business Overview Table 85. Mallinckrodt Pharmaceuticals Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Mallinckrodt Pharmaceuticals Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio Table 87. Mallinckrodt Pharmaceuticals Recent Development Table 88. Lupin Limited Company Information Table 89. Lupin Limited Business Overview Table 90. Lupin Limited Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Lupin Limited Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio Table 92. Lupin Limited Recent Development Table 93. Johnson & Johnson Company Information Table 94. Johnson & Johnson Business Overview Table 95. Johnson & Johnson Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Johnson & Johnson Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio Table 97. Johnson & Johnson Recent Development Table 98. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2021-2026) & (US$ Million) Table 100. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country (2021-2026) Table 101. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share Forecast by Country (2027-2032) Table 103. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 104. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2021-2026) & (US$ Million) Table 105. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country (2021-2026) Table 106. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Forecast by Country (2027-2032) & (US$ Million) Table 107. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share Forecast by Country (2027-2032) Table 108. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2021-2026) & (US$ Million) Table 110. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country (2021-2026) Table 111. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share Forecast by Country (2027-2032) Table 113. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2021-2026) & (US$ Million) Table 115. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country (2021-2026) Table 116. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share Forecast by Country (2027-2032) Table 118. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2021-2026) & (US$ Million) Table 120. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country (2021-2026) Table 121. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share Forecast by Country (2027-2032) Table 123. Research Programs/Design for This Report Table 124. Authors List of This Report Table 125. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Image Figure 3. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size (2021-2032) & (US$ Million) Figure 5. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Region: 2025 VS 2032 Figure 6. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Region (2021-2032) Figure 7. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Stimulants Image Figure 13. Global Stimulants Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Non-stimulants Image Figure 15. Global Non-stimulants Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Type 2025 VS 2032 Figure 18. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Share by Type (2021-2032) Figure 19. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Share by Type (2021-2032) Figure 21. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Share by Type (2021-2032) Figure 23. Hospital Image Figure 24. Global Hospital Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Clinic Image Figure 26. Global Clinic Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Others Image Figure 28. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Application 2025 VS 2032 Figure 31. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Share by Application (2021-2032) Figure 32. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Share by Application (2021-2032) Figure 33. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Share by Application (2021-2032) Figure 34. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Share by Application (2021-2032) Figure 35. Middle East and Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Share by Application (2021-2032) Figure 36. Global Top 5 and 10 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Players Market Share by Revenue in 2025 Figure 37. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 38. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 39. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country: 2021 VS 2025 VS 2032 Figure 40. North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country (2021-2032) Figure 41. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country (2021-2032) Figure 44. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country (2021-2032) Figure 47. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Latin America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country (2021-2032) Figure 50. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Share by Country (2021-2032) Figure 53. Years Considered Figure 54. Research Process Figure 55. Key Executives Interviewed

Scope & coverage.

Types
  • Stimulants
  • Non-stimulants
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • The Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer Inc.
  • Supernus Pharmaceutical,Inc.
  • purdue Pharma L.P.
  • Neos Therapeutics Inc.
  • Mallinckrodt Pharmaceuticals
  • Lupin Limited
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Region (2021-2032)
  5. 1.4.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Region (2021-2026)
  6. 1.4.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Region (2027-2032)
  7. 1.5 Key Regions Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size (2021-2032)
  8. 1.5.1 North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (2021-2032)
2 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Stimulants
  3. 2.1.2 Non-stimulants
  4. 2.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Type
  5. 2.2.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Regions
  9. 2.3.1 North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Type (2021-2026)
3 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospital
  3. 3.1.2 Clinic
  4. 3.1.3 Others
  5. 3.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Application
  6. 3.2.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Regions
  10. 3.3.1 North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Trends
  2. 4.2 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Drivers
  3. 4.3 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Opportunities and Challenges
  4. 4.4 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue (2021-2026)
  2. 5.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Key Company Headquarters & Area Served
  4. 5.4 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Company, Product Type & Application
  5. 5.5 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Attention-Deficit Hyperactivity Disorder (ADHD) Medications Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 The Takeda Pharmaceutical Company Limited
  2. 6.1.1 The Takeda Pharmaceutical Company Limited Company Information
  3. 6.1.2 The Takeda Pharmaceutical Company Limited Business Overview
  4. 6.1.3 The Takeda Pharmaceutical Company Limited Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 The Takeda Pharmaceutical Company Limited Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
  6. 6.1.5 The Takeda Pharmaceutical Company Limited Recent Developments
  7. 6.2 Novartis AG
  8. 6.2.1 Novartis AG Company Information
  9. 6.2.2 Novartis AG Business Overview
  10. 6.2.3 Novartis AG Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Novartis AG Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
  12. 6.2.5 Novartis AG Recent Developments
  13. 6.3 Eli Lilly and Company
  14. 6.3.1 Eli Lilly and Company Company Information
  15. 6.3.2 Eli Lilly and Company Business Overview
  16. 6.3.3 Eli Lilly and Company Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Eli Lilly and Company Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
  18. 6.3.5 Eli Lilly and Company Recent Developments
  19. 6.4 Pfizer Inc.
  20. 6.4.1 Pfizer Inc. Company Information
  21. 6.4.2 Pfizer Inc. Business Overview
  22. 6.4.3 Pfizer Inc. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Pfizer Inc. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
  24. 6.4.5 Pfizer Inc. Recent Developments
  25. 6.5 Supernus Pharmaceutical,Inc.
  26. 6.5.1 Supernus Pharmaceutical,Inc. Company Information
  27. 6.5.2 Supernus Pharmaceutical,Inc. Business Overview
  28. 6.5.3 Supernus Pharmaceutical,Inc. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Supernus Pharmaceutical,Inc. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
  30. 6.5.5 Supernus Pharmaceutical,Inc. Recent Developments
  31. 6.6 purdue Pharma L.P.
  32. 6.6.1 purdue Pharma L.P. Company Information
  33. 6.6.2 purdue Pharma L.P. Business Overview
  34. 6.6.3 purdue Pharma L.P. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 purdue Pharma L.P. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
  36. 6.6.5 purdue Pharma L.P. Recent Developments
  37. 6.7 Neos Therapeutics Inc.
  38. 6.7.1 Neos Therapeutics Inc. Company Information
  39. 6.7.2 Neos Therapeutics Inc. Business Overview
  40. 6.7.3 Neos Therapeutics Inc. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Neos Therapeutics Inc. Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
  42. 6.7.5 Neos Therapeutics Inc. Recent Developments
  43. 6.8 Mallinckrodt Pharmaceuticals
  44. 6.8.1 Mallinckrodt Pharmaceuticals Company Information
  45. 6.8.2 Mallinckrodt Pharmaceuticals Business Overview
  46. 6.8.3 Mallinckrodt Pharmaceuticals Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Mallinckrodt Pharmaceuticals Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
  48. 6.8.5 Mallinckrodt Pharmaceuticals Recent Developments
  49. 6.9 Lupin Limited
  50. 6.9.1 Lupin Limited Company Information
  51. 6.9.2 Lupin Limited Business Overview
  52. 6.9.3 Lupin Limited Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Lupin Limited Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
  54. 6.9.5 Lupin Limited Recent Developments
  55. 6.10 Johnson & Johnson
  56. 6.10.1 Johnson & Johnson Company Information
  57. 6.10.2 Johnson & Johnson Business Overview
  58. 6.10.3 Johnson & Johnson Attention-Deficit Hyperactivity Disorder (ADHD) Medications Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Johnson & Johnson Attention-Deficit Hyperactivity Disorder (ADHD) Medications Product Portfolio
  60. 6.10.5 Johnson & Johnson Recent Developments
7 North America
  1. 7.1 North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2021-2026)
  3. 7.3 North America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2021-2026)
  3. 8.3 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2021-2026)
  3. 10.3 South America Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Attention-Deficit Hyperactivity Disorder (ADHD) Medications Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst